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j ourna l homepage: www.eb iomed ic ine.comEditorialGetting Healthier Through Microbiome MakeoverIn this issue of EBioMedicine, Liping Zhao and colleagues show that
children with obesity have similar gut microbiota dysbiosis regardless
of their geneticmakeup,whether it is simple obesity (no underlying pa-
thology) or genetic obesity (Prader–Willi syndrome). Furthermore,
their microbiome proﬁle can be changed by a 1-month dietary
intervention. Interestingly, the authors also show that transfer of pre-
intervention fecal microbiota from these children to germ-free mice re-
capitulates key obesity-related traits, an effect that is not seen if post-
intervention fecal microbiota from the same children is transplanted,
suggesting a possible causative contribution of gutmicrobiota to obesity
development.
Microbes inhabit various niches of the human body, from the skin to
oronasal and urogenital cavities, but the vast majority is found in the
human gastrointestinal tract. Microbes outnumber human cells at a
ratio of 10 to 1, and microbial genes outnumber human genes by over
100 to 1. Commensal microbes have an important role in digesting
food and providing nutrients, in educating our immune system and in
protecting us from infection. More than 30% of small molecules found
in human blood are derived from microbes. Using high-throughput
molecular technologies, large collaborative projects such as the
European Commission-funded MetaHIT and the US NIH-funded
HumanMicrobiome Project are aiding the discovery of increasingly im-
portant insights into the role of the microbiome in human health.
The ﬁeld of microbiomics holds a lot of hope, but at the same time,
microbiome research also has the potential to create much hype. We
must be cautious in interpreting overly positive news headlines, be-
cause most studies to date are based on small numbers, their ﬁndings
are often preliminary, descriptive, and sometimes even contradictory.
The human microbiome has been linked to a plethora of diseases,
ranging from gastrointestinal conditions (inﬂammatory bowel disease,
colorectal cancer) and metabolic syndromes (diabetes, obesity), to
seemingly unrelated diseases such as rheumatoid arthritis, cardiovascu-
lar diseases (atherosclerosis), neurological disorders (multiple sclerosis,
Alzheimer's disease), and mental health (anxiety, depression, autism).
But how many of these links are true causal relationships? In
microbiome research, many confounding factors need to be controlled
for— for example, diet is amajor confounder that can affect both gutmi-
crobiota and obesity. For therapeutic applications, evidence for causality
is crucial along with the underlying mechanisms of action. Thus, even
when a correlation between the microbiome and health is sufﬁciently
robust and reproducible, the application of such ﬁndings beyond diag-
nostic or prognostic use is not immediately apparent. Researchers ur-
gently need to transition away from purely descriptive work toward
more mechanistic studies.http://dx.doi.org/10.1016/j.ebiom.2015.08.024
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article underAnother signiﬁcant hurdle is howwellmicrobiome researchﬁndings
are translated in real-life situations. The majority of translational work
to date has been focused on preclinical experiments using germ-free an-
imals, which do not represent the animal's natural state. Nonetheless,
germ-free animals have been a vital tool in microbiome research and
have helped answer simple questions, such aswhether behavioral traits
can be transferred via fecal microbiota transplant (FMT). Germ-free
mice receiving FMT from patients with irritable bowel syndrome (IBS)
developed leaky intestines and produced proinﬂammatorymetabolites,
many of which are known neurotransmitters. These animals also
displayed anxious behavior, and indeed anxiety and depression are
often observed in IBS patients, but the pathogenesis remains elusive.
Ongoing research into the brain–gut axis has also shed light on how
glia cells and neurons of the brain and gut may communicate. Observa-
tions such as these can be pieced together to build amore complete pic-
ture of the complex interactions and associations.
While we should not let our interpretations and related clinical deci-
sions be driven by the hyperboles surrounding how gutmicrobes might
affect human health, there are some useful advances in our knowledge
that allow for clinical application. Clostridium difﬁcile infection (CDI),
which most commonly occurs in individuals whose gut microbiota
have been displaced as a result of antibiotic treatment, can manifest as
severe diarrhea especially in those over 65 years of age. Stopping antibi-
otics (to allow gut microbiota to recover) or treating with CDI-speciﬁc
antibiotics (e.g., vancomycin) is not always successful — and among
those with treatment failure, one in three will die. FMT is a newly
available treatment for relapsed CDI in the UK and USA, in which fecal
microbiota from a healthy donor can alleviate diarrheal symptoms
within 1–2 days for more than 90% of patients.
The paper by Zhao and colleagues suggests a housekeeping role for
Biﬁdobacterium species in maintaining gut homeostasis and a healthy
gut ecosystem. Whether or not Biﬁdobacterium plays an active role in
the success of FMT in CDI treatment remains to be determined. But in
keeping with the US NIH Precision Medicine Initiative, future research
should focus on delineating themicrobial subspecies that have a positive
effect on CDI treatment, which would inform a better-characterized,
mechanistically-deﬁned, microbiome-targeted intervention. Although
CDI is currently the only indication for which FMT is approved outside
of a clinical trial, the hundreds of other ongoing FMT trials will hopefully
soon yield useful and effective interventions for many other health
conditions.
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